We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NeoStem (NBS) Subsidiary, PCT, gains NEW CLIENT

29 Dec 2014 12:10 PM <--
16 Jan 2013 11:02 AM

Return to NeoStem (NBS) Subsidiary, PCT, gains NEW CLIENT
8:04AM Neostem subsidiary, Progenitor Cell Therapy, enters into a cell therapy manufacturing services agreement with Adaptimmune ( NBS) 0.63 : Co announces its subsidiary, Progenitor Cell Therapy, together with Adaptimmune Limited and Adaptimmune, announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications. PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials.